Masumi Ueda

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa — South Africa

Medicine · Health Sciences

22h-index2.1kcitations208works10.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(37), Acute Myeloid Leukemia Research(35), Cancer-related gene regulation(25), RNA Interference and Gene Delivery(16), Acute Lymphoblastic Leukemia research(16)

Publications207 total

Donor-derived del[20q] following allogeneic-hematopoietic cell transplantation: a case with 26-year follow-up and literature review
Bone Marrow Transplantation·2026Open Access
Impact of Severe Infections on Non-Relapse Mortality after Allogeneic HCT: A Post-Hoc Analysis of a Randomized Phase II Study Comparing Post-Transplantation Cyclophosphamide (PTCy) and Non-Ptcy-Based GVHD Prophylaxis
Transplantation and Cellular Therapy·2026
Genome-Wide Epigenetic Comparisons in Long-Term Donor-Recipient Pairs Decades after Allogeneic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2026
Ethics Consult Service Hematopoietic Cell Transplantation and Cellular Immunotherapy at a Regional Quaternary Comprehensive Cancer Center
Transplantation and Cellular Therapy·2026
Impact of Obesity on GVHD Following Post-Transplantation Cyclophosphamide in Patients Undergoing Allogeneic Hematopoietic Cell Transplant
Transplantation and Cellular Therapy·2026
Fear of Cancer Recurrence in Hematopoietic Cell Transplantation Survivors
Transplantation and Cellular Therapy·2026
Higher Incidence of Severe Acute GVHD and NRM Following High Dose Cyclophosphamide Based Conditioning Regimen in Overweight and Obese Patients Undergoing Allogeneic HCT
Transplantation and Cellular Therapy·2026
Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Clinical Infectious Diseases·2026
Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Clinical and Humoral Risk Factors for Infection
Open Forum Infectious Diseases·2025Open Access
Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506
Blood·2025
Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib
Blood·2025Open Access
Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation
Journal of Clinical Oncology·2025· 1 cited
Cytomegalovirus Viral Load Continues to Predict Poor Outcomes in Adults and Children Despite Improved Hematopoietic Cell Transplantation Success
Open Forum Infectious Diseases·2025· 2 citedOpen Access
Impact of transplant conditioning, <i>NPM1</i> mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
Blood Advances·2025· 5 citedOpen Access
ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients
Bone Marrow Transplantation·2025· 4 citedOpen Access
Donor-Recipient Telomere Dynamics in Long –Term Survivors of Allogenic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2025
Late Effects and Quality of Life in Long-Term Survivors Following Hematopoietic Cell Transplantation and Post-Transplantation Cyclophosphamide-Based GvHD Prophylaxis
Transplantation and Cellular Therapy·2025
A Randomized Phase II Study Comparing Cyclosporine and Sirolimus Combined with MMF or Post-Transplant Cyclophosphamide As Gvhd Prophylaxis after HLA-Matched or -Mismatched Unrelated Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced-Intensity Conditioning
Transplantation and Cellular Therapy·2025
Characterization of Chronic Graft-Versus-Host Disease Onset, Severity, and Treatment after Post-Transplantation Cyclophosphamide-Based Gvhd Prophylaxis
Transplantation and Cellular Therapy·2025
Twenty-Six-Year Follow-up of Donor-Derived Del(20q) after Allogeneic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2025Open Access
page 1 of 11Next →

Frequent Co-authors

Marcos de Lima(7), Stephanie J. Lee(7), Brenda M. Sandmaier(6), Michael Boeckh(6), Paul A. Carpenter(6), Yi‐Bin Chen(5), Hillard M. Lazarus(5), Hu Xie(5), Keith R. Jerome(5), Rachel B. Salit(5), Mary E.D. Flowers(5), Marco Mielcarek(5), Catherine Liu(4), Steven M. Devine(4), Jirô Arata(4), David N. Wald(4), Danniel Zamora(4), Elizabeth F. Krakow(4), Laura Connelly‐Smith(4), Steven A. Pergam(3)